These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
704 related articles for article (PubMed ID: 1447905)
1. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905 [TBL] [Abstract][Full Text] [Related]
2. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
4. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368 [TBL] [Abstract][Full Text] [Related]
5. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500 [TBL] [Abstract][Full Text] [Related]
6. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
8. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Jones P; Kafonek S; Laurora I; Hunninghake D Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin. Del Puppo M; Rauli S; Galli Kienle M Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435 [TBL] [Abstract][Full Text] [Related]
10. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat. Bueld JE; Bannenberg G; Netter KJ Pharmacol Toxicol; 1996 Apr; 78(4):229-34. PubMed ID: 8861780 [TBL] [Abstract][Full Text] [Related]
11. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861 [TBL] [Abstract][Full Text] [Related]
12. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens. Kalinowski SS; Tanaka RD; Mosley ST Exp Eye Res; 1991 Aug; 53(2):179-86. PubMed ID: 1915674 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275 [TBL] [Abstract][Full Text] [Related]
14. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Gerson RJ; MacDonald JS; Alberts AW; Chen J; Yudkovitz JB; Greenspan MD; Rubin LF; Bokelman DL Exp Eye Res; 1990 Jan; 50(1):65-78. PubMed ID: 2307197 [TBL] [Abstract][Full Text] [Related]
15. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225 [TBL] [Abstract][Full Text] [Related]
16. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667 [TBL] [Abstract][Full Text] [Related]
17. Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits. Behrens-Baumann W; Thiery J Res Exp Med (Berl); 1992; 192(1):7-11. PubMed ID: 1570417 [TBL] [Abstract][Full Text] [Related]
18. A review of clinical trials comparing HMG-CoA reductase inhibitors. Illingworth DR; Tobert JA Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304 [TBL] [Abstract][Full Text] [Related]
19. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Lintott CJ; Scott RS; Sutherland WH; Bremer J Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151 [TBL] [Abstract][Full Text] [Related]
20. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin. De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]